Company Overview
Fortrea Holdings Inc. operates as a contract research organization dedicated to delivering biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers globally. The company functions within the Healthcare sector and specifically targets the Biotechnology industry, providing specialized services such as clinical pharmacology, clinical research units, and external partnerships to advance medical innovation. This entity employs a significant workforce of 13,871 individuals, reflecting its substantial operational footprint within the global research landscape. The company holds a market capitalization of $895.73M and generated revenue of $2.72B over the trailing twelve months, positioning it as a major player capable of supporting large-scale clinical trials and development programs for its diverse client base.
Financial Health
Fortrea Holdings Inc. reported a revenue of $2.72B in the trailing twelve months, yet recorded a net income of $-986,200,000, revealing a significant gap between top-line sales and bottom-line profitability driven by high operational costs or investment expenses. Despite the substantial net loss, the company achieved an EBITDA of $41.50M, suggesting that core operating cash generation remains positive even before interest and tax considerations. The business generated free cash flow of $196.05M, which indicates a strong capacity to manage liquidity, fund internal projects, and potentially service debt obligations without relying solely on external financing. The company's profitability is further contextualized by a gross margin of 18.5%, an operating margin of 1.3%, and a profit margin of -36.2%, illustrating that while the cost of goods sold is managed, significant expenses related to research, administration, or restructuring are compressing overall profitability. On the balance sheet, Fortrea holds $174.60M in cash against total debt of $1.12B, resulting in a debt-to-equity ratio of 198.26, which characterizes the capital structure as highly leveraged with obligations far exceeding available liquid assets. The current ratio stands at 0.98, indicating that current liabilities slightly exceed current assets and signaling potential pressure on short-term liquidity if cash inflows do not accelerate. Return on Equity is recorded at -102.4% and Return on Assets at -0.6%, metrics that highlight how the company's current operational losses are negatively impacting shareholder value and asset efficiency.
Valuation Assessment
The valuation profile of Fortrea Holdings Inc. is characterized by a trailing P/E ratio of N/A due to the lack of recent earnings, contrasted with a forward P/E of 9.94, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is 1.58, suggesting that the market values the company at a moderate premium over its net book value, potentially reflecting the intangible value of its clinical trial data and client relationships. Alternative valuation metrics such as a price-to-sales ratio of 0.33 and an EV/EBITDA of 44.30 provide additional context, with the low multiple to sales indicating the stock is priced relative to its massive revenue base despite current earnings volatility. The stock has historically traded between a 52-week high of $18.67 and a 52-week low of $3.97, a range that encompasses a volatility of over 300% and places the current price dynamics in a highly sensitive position relative to recent market lows. The beta of 1.78 indicates that the stock's price volatility is significantly higher than the broader market, moving approximately 1.78 times as much as the index and exposing investors to elevated systemic risk.
Growth & Income
Fortrea Holdings Inc. experienced a revenue growth rate of -5.2% year-over-year, while earnings growth is listed as N/A due to the company's current loss position, implying that the business is currently contracting in revenue terms rather than expanding its top line. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead retains all earnings to fund operations and potentially reduce its high debt load. The absence of dividend payments aligns with the company's reinvestment strategy, where resources are directed toward maintaining its clinical research units and partnerships rather than providing passive income to investors. Overall, the growth and income profile for Fortrea Holdings Inc. is defined by negative revenue momentum, significant leverage, and a complete absence of current income distributions, presenting a high-risk, high-volatility equity profile within the biotechnology sector.